Loading...
XSTOHNSA
Market cap230mUSD
Dec 23, Last price  
37.50SEK
1D
-3.55%
1Q
-6.53%
Jan 2017
-67.81%
IPO
363.54%
Name

Hansa Biopharma AB

Chart & Performance

D1W1MN
XSTO:HNSA chart
P/E
—
P/S
18.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.51%
Rev. gr., 5y
109.06%
Revenues
134m
-13.22%
103,6752,983,7594,448,1861,282,2192,618,8351,727,0174,716,0005,434,0002,579,0003,442,0003,358,0003,364,0006,098,00033,878,000154,525,000134,094,000
Net income
-832m
L+36.09%
-2,558,185-15,812,150-18,843,239-24,572,021-16,466,035-17,561,999-29,042,000-66,266,000-111,129,000-176,660,000-247,974,000-360,009,000-420,853,000-548,282,000-611,134,000-831,720,000
CFO
-756m
L+50.31%
-15,576,021-13,792,299-18,093,957-27,139,111-20,633,032-14,865,322-23,623,000-57,799,000-94,563,000-150,105,000-204,560,000-334,775,000-290,274,000-481,168,000-502,733,000-755,654,000
Earnings
Jan 31, 2025

Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://www.hansabiopharma.com/
IPO date
Oct 17, 2007
Employees
162
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
134,094
-13.22%
154,525
356.12%
33,878
455.56%
Cost of revenue
924,967
722,582
573,458
Unusual Expense (Income)
NOPBT
(790,873)
(568,057)
(539,580)
NOPBT Margin
Operating Taxes
908
1,155
152
Tax Rate
NOPAT
(791,781)
(569,212)
(539,732)
Net income
(831,720)
36.09%
(611,134)
11.46%
(548,282)
30.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
396,196
BB yield
-17.92%
Debt
Debt current
7,503
7,165
6,888
Long-term debt
881,130
812,418
63,870
Deferred revenue
1
29,500
47,020
Other long-term liabilities
5,297
5,949
8,079
Net debt
156,573
(676,596)
(818,203)
Cash flow
Cash from operating activities
(755,654)
(502,733)
(481,168)
CAPEX
(284)
(3,331)
(2,399)
Cash from investing activities
(284)
229,313
(2,399)
Cash from financing activities
(7,545)
1,117,681
(4,857)
FCF
(783,018)
(559,264)
(575,816)
Balance
Cash
732,060
1,496,179
888,961
Long term investments
Excess cash
725,355
1,488,453
887,267
Stockholders' equity
(3,248,181)
(2,416,040)
(1,813,491)
Invested Capital
3,952,370
3,844,731
2,661,352
ROIC
ROCE
EV
Common stock shares outstanding
52,540
44,924
44,473
Price
26.20
-46.77%
49.22
-44.57%
88.80
-63.06%
Market cap
1,376,550
-37.75%
2,211,159
-44.01%
3,949,243
-61.05%
EV
1,533,123
1,534,563
3,131,040
EBITDA
(771,081)
(556,003)
(530,974)
EV/EBITDA
Interest
105,520
43,666
694
Interest/NOPBT